Third Interim Analysis from B-MORE: A 24-Month Prospective, Multicentre, Non‑Interventional
Study on the Real-Word Effectiveness and Usage of Recombinant Factor IX Fc (rFIXFc)
in Haemophilia B
Authors
H Glosli
1
Oslo University Hospital, Centre for Rare Disorders, Oslo, Norway
F Langer
2
University Medical Centre Hamburg-Eppendorf, II. Medical Clinic and Polyclinic, Hamburg,
Germany
O Benitez Hidalgo
3
Vall d'Hebron Hospital, Hemophilia Unit, Hematology Department, Barcelona, Spain
B Nolan
4
Children's Health Ireland at Crumlin, Children’s Coagulation Centre, Dublin,
Ireland
A Olsson
5
Sahlgrenska University Hospital, Department of Medicine, Region Västra Götaland, Gothenburg,
Sweden
6
University of Gothenburg, The Sahlgrenska Academy, Department of Internal Medicine,
Institute of Medicine, Gothenburg, Sweden
M Scott
7
Manchester Royal Infirmary, Department of Clinical Haematology, Manchester, UK
H Ahlin
8
Sobi, Observational Research, Stockholm, Sweden
E Bednar
9
Sobi, Global Medical Affairs and Clinical Development, Stockholm, Sweden
E Santagostino
9
Sobi, Global Medical Affairs and Clinical Development, Stockholm, Sweden
